Understanding and treating abdominal pain and spasms in organic gastrointestinal diseases: Inflammatory bowel disease and biliary diseases

Journal of Clinical Gastroenterology

Volumn 45, Issue SUPPL. 2, 2011, Pages

  Makharia, Govind K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

biliary colic; functional gastrointestinal disease; inflammatory bowel disease

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CIMETROPIUM; CYCLOOXYGENASE 2 INHIBITOR; MEBEVERINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PINAVERIUM; ROFECOXIB; SEROTONIN; SPASMOLYTIC AGENT; SUBSTANCE P; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRIMEBUTINE; VANILLOID RECEPTOR;

ABDOMINAL PAIN; BILIARY TRACT DISEASE; BILIARY TRACT PAIN; BIOSYNTHESIS; DAILY LIFE ACTIVITY; ENTERITIS; EPIDURAL ANESTHESIA; HEALTH CARE UTILIZATION; HEART EJECTION FRACTION; HUMAN; INTESTINAL SPASM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANALGESICS; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BILIARY TRACT DISEASES; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; PARASYMPATHOLYTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPASM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958827790     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31821fbd82     Document Type: Review

References (62)

1. Sandler RS, Stewart WF, Liberman JN, et al. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci. 2000;45:1166-1171. (Pubitemid 30409462)
2. Dix P, Sandhar B, Murdoch J, et al. Pain on medical wards in a district general hospital. Br J Anaesth. 2004;92:235-237. (Pubitemid 38159663)
3. Melotti RM, Samolsky-Dekel BG, Ricchi E, et al. Pain prevalence and predictors among inpatients in a major Italian teaching hospital: a baseline survey towards a pain free hospital. Eur J Pain. 2005;9:485-495. (Pubitemid 41219781)
4. Vallano A, Malouf J, Payrulet P, et al. Prevalence of pain in adults admitted to Catalonian hospitals: a cross-sectional study. Eur J Pain. 2006;10:721-731. (Pubitemid 44416283)
5. Makharia GK, Verma AK, Amarchand R, et al. Prevalence of irritable bowel syndrome: a Community Based Study From Northern India. J Neurogastroenterol Motil. 2011;17:82-87.
6. Quigley EM, Locke GR, Mueller-Lissner S, et al. Prevalence and management of abdominal cramping and pain: a multinational survey. Aliment Pharmacol Ther. 2006;24:411-419. (Pubitemid 43972910)
7. Cartwright SL, Knudson MP. Evaluation of acute abdominal pain in adults. Am Fam Physician. 2008;77:971-978.
8. Lacy BE, Cash BD. A 32-year-old woman with chronic abdominal pain. JAMA. 2008;299:555-565. (Pubitemid 351214253)
9. Cervero F. Visceral versus somatic pain: similarities and differences. Dig Dis. 2009;27(Suppl. 1):3-10.
10. DeBanto JR, Varilek GW, Haas L. What could be causing chronic abdominal pain? Anything from common peptic ulcers to uncommon pancreatic trauma. Postgrad Med.1999;106:141-146. (Pubitemid 29426863)
11. Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:778-788.
12. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol. 2005;100:2225-2229.
13. Edwards JT, Radford-Smith GL, Florin TH. Chronic narcotic use in inflammatory bowel disease patients: prevalence and clinical characteristics. J Gastroenterol Hepatol. 2001;16:1235-1238. (Pubitemid 34088270)
14. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
15. Swoger JM, Binion DG. Supportive therapy in IBD: what additional diagnoses and conditions must be treated? Dig Dis. 2010;28:452-462.
16. Long MD, Drossman DA. Inflammatory bowel disease, irritable bowel syndrome, or what? A challenge to the functional-organic dichotomy. Am J Gastroenterol. 2010;105:1796-1798.
17. Spiller RC. Overlap between irritable bowel syndrome and inflammatory bowel disease. Dig Dis. 2009;27(Suppl. 1):48-54.
18. Drossman DA. Functional versus organic: an inappropriate dichotomy for clinical care. Am J Gastroenterol. 2006;101:1172-1175. (Pubitemid 43829976)
19. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011. [Epub ahead of print].
20. Gwee KA. Post-infectious irritable bowel syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J Neurogastroenterol Motil. 2010;16:30-34.
21. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7:163-173.
22. Bayless TM, Harris ML. Inflammatory bowel disease and irritable bowel syndrome. Med Clin North Am. 1990;74:21-28.
23. Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910-1915.
24. Sood A, Midha V, Sood N, et al. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 2003;52:1587-1590.
25. Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis-how much is irritable bowel syndrome? Clin Gastroenterol Hepatol. 2006;4:614-620.
26. Simrén M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002;97:389-396.
27. Farrokhyar F, Marshall JK, Easterbrook B, et al. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis. 2006;12:38-46. (Pubitemid 43032450)
28. Ansari R, Attari F, Razjouyan H, et al. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur J Gastroenterol Hepatol. 2008;20:46-50. (Pubitemid 350307488)
29. Keohane J, O'Mahony C, O'Mahony L, et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol. 2010;105:1788-1794.
30. Bielefeldt K, Christianson JA, Davis BM. Basic and clinical aspects of visceral sensation: transmission to the CNS. Neurogastroenterol Motil. 2005;17:488-499. (Pubitemid 41075990)
31. Adam B, Liebregts T, Gschossmann JM, et al. Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model. Pain. 2006;123:179-186. (Pubitemid 43816772)
32. Jones RCW III, Xu L, Gebhart GF. The mechanosensitivity of mouse colon afferent fibers and their sensitization by inflammatory mediators require transient receptor potential vanilloid 1 and acid-sensing ion channel 3. J Neurosci. 2005;25:10981-10989. (Pubitemid 41692628)
33. Szallasi A, Cortright DN, Blum CA, et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov. 2007;6:357-372. (Pubitemid 46705200)
34. Akbar A, Yiangou Y, Facer P, et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut. 2010;59:767-774.
35. Buéno L, Fioramonti J, Garcia-Villar R. Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain. Am J Physiol Gastrointest Liver Physiol. 2000;278:G670-G676.
36. Shinoda M, Feng B, Gebhart GF. Peripheral and central P2X receptor contributions to colon mechanosensitivity and hypersensitivity in the mouse. Gastroenterology. 2009;137:2096-104.
37. Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. Nat Med. 2010;16:1248-1257.
38. Mawe GM, Coates MD, Moses PL. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23:1067-1076. (Pubitemid 43779345)
39. Minderhoud IM, Oldenburg B, Schipper ME, et al. Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission. Clin Gastroenterol Hepatol. 2007;5:714-720. (Pubitemid 46830050)
40. Ginsburg PM, Bayless TM. How can IBD be distinguished from IBS? Inflamm Bowel Dis. 2008;14(Suppl. 2):S152-S154.
41. Grover M, Herfarth H, Drossman DA. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7:48-53.
42. Sidhu R, Wilson P, Wright A, et al. Faecal lactoferrin: a novel test to differentiate between the irritable and inflamed bowel? Aliment Pharmacol Ther. 2010;31:1365-1370.
43. Manolakis AC, Kapsoritakis AN, Georgoulias P, et al. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol. 2010;10:118.
44. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14:32-39. (Pubitemid 351196866)
45. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377-1390.
46. Tanaka M. Function and dysfunction of the sphincter of Oddi. Dig Surg. 2010;27:94-99.
47. Hansel SL, DiBaise JK. Functional gallbladder disorder: gallbladder dyskinesia. Gastroenterol Clin North Am. 2010;39:369-379.
48. Li WG, Luo XY, Johnson AG, et al. One-dimensional models of the human biliary system. J Biomech Eng. 2007;129:164-173. (Pubitemid 46722329)
49. Li WG, Luo XY, Hill NA, et al. A mechanical model for CCK-induced acalculous gallbladder pain. Ann Biomed Eng. 2011;39:786-800.
50. Helfand M, Freeman M. Assessment and management of acute pain in adult medical inpatients: a systematic review. Pain Med. 2009;10:1183-1189.
51. BasurtoOñ a X, Robles Perea L. Anti-inflammatory drugs for biliary colics: systematic review and meta-analysis of randomized controlled trials. Gastroenterol Hepatol. 2008;31:1-7.
52. Maev IV, KucheriavyǐIu A, Sviridova AV. Possibilities of pharmacotherapy in the treatment of abdominal pain syndrome in patients with chronic pancreatitis. Eksp Klin Gastroenterol. 2007;6:103-109.
53. Lipnitskiǐ EM, Isakova OV, Dzhadzhanidze AD, et al. Efficacy of duspatalin in the treatment and prophylaxis of postcholecystectomic syndrome. Eksp Klin Gastroenterol. 2008;3:86-93.
54. Holdgate A, Pollock T. Non-steroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Cochrane Database Syst Rev. 2005;2:CD004137.
55. Feagins LA, Cryer BL. Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Dig Dis Sci. 2010;55:226-232.
56. Kefalakes H, Stylianides TJ, Amanakis G, et al. Exacerbation of inflammatory bowel diseases associated with the use of non-steroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol. 2009;65:963-970.
57. Cipolla G, Crema F, Sacco S, et al. Nonsteroidal antiinflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002;46:1-6. (Pubitemid 35300786)
58. Reinisch W, Miehsler W, Dejaco C, et al. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther. 2003;17:1371-1380. (Pubitemid 36774144)
59. Hatoum OA, Binion DG, Otterson MF, et al. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology. 2003;125:58-69. (Pubitemid 36799107)
60. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313.
61. Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther. 1996;10:787-793. (Pubitemid 26340210)
62. Washington N, Ridley P, Thomas C, et al. Mebeverine decreases mass movements and stool frequency in lactulose-induced diarrhoea. Aliment Pharmacol Ther. 1998;12:583-588. (Pubitemid 28289449)